Details of the Drug

General Information of Drug (ID: DMQM9S0)

Drug Name

Palivizumab

Synonyms

Synagis; Abbosynagis (TN); Palivizumab (INN); Palivizumab (genetical recombination); Synagis (TN); Palivizumab (genetical recombination) (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Respiratory syncytial virus infection	1C80	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

ATC Code

J06BD01: Palivizumab

J06BD: Antiviral monoclonal antibodies

J06B: IMMUNOGLOBULINS

J06: IMMUNE SERA AND IMMUNOGLOBULINS

J: ANTIINFECTIVES FOR SYSTEMIC USE

Drug Type

Monoclonal antibody

Sequence

QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKD
YNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 18 - 20 days (in adults) [2]
Metabolism: The drug is metabolized via opsonization via the reticuloendothelial system []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Respiratory syncytial virus protein F (RSV F)	TT57ID8	FUS_HRSVA	Modulator	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.